It sounds very good to me. I picked out the two excerpts below: ----- Santarus has the exclusive right to commercialize authorized generic versions of the Glumetza products. Santarus will pay no additional sales milestones to Depomed as was required under the prior Promotion Agreement.
During the term, Depomed will continue to manage the ongoing patent infringement lawsuits against Sun Pharmaceutical Industries ------ Depomed really sent SNTS back with their manufacturing flaws over a year ago, and I think this is somewhat of a makeup proposal to SNTS. It will be interesting to hear what they say on the conference call tonight, which I am eagerly looking forward to!